cell
cell
中文   |   العربية   |   Ελληνικά
Arrange a Consultation
   Reviews | Leave a Review
cell

About Professor Nutting

Publications

For an updated list of publications access www.ncbi.nlm.nih.gov/sites/entrez and search under “Nutting C” to get the latest papers for our research group.

Papers published or “in press” for peer-reviewed Journals

Original Articles

  1. 1. Rooney KP, Miah AB, Bhide SA, Guerrero-Urbano MT, Sharabiani MT, Newbold KL, Grove L, Harrington KJ, Nutting CM. Intensity modulated radiotherapy in locally advanced thyroid cancer: Outcomes of a sequential phase I dose-escalation study. Radiother Oncol. 2018 Apr;127(1):43-48.
  2. 2. Hague C, Foran B, Hall E, Guild S, Joseph O, Moule R, Nutting C, Parsons S, Prestwich R, Slevin N, West C, Thomson D. Patient Involvement in the Design of a Phase III Trial Comparing Intensity-modulated Proton Therapy and Intensity-modulated Radiotherapy for Oropharyngeal Cancer. Clin Oncol (R Coll Radiol). 2018 May;30(5):274-276.
  3. 3. Petkar I, Bhide S, Newbold K, Harrington K, Nutting C. Practice patterns for the radical treatment of nasopharyngeal cancer by head and neck oncologists in the United Kingdom. Br J Radiol. 2018 May;91(1085):20170590.
  4. 4. Gurney-Champion OJ, McQuaid D, Dunlop A, Wong KH, Welsh LC, Riddell AM, Koh DM, Oelfke U, Leach MO, Nutting CM, Bhide SA, Harrington KJ, Panek R, Newbold KL. MRI-based Assessment of 3D Intrafractional Motion of Head and Neck Cancer for Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):306-316.
  5. 5. Wong KH, Panek R, Dunlop A, Mcquaid D, Riddell A, Welsh LC, Murray I, Koh DM, Leach MO, Bhide SA, Nutting CM, Oyen WJ, Harrington KJ, Newbold KL. Changes in multimodality functional imaging parameters early during chemoradiation predict treatment response in patients with locally advanced head and neck cancer. Eur J Nucl Med Mol Imaging. 2018 May;45(5):759-767. doi: 10.1007/s00259-017-3890-2. Epub 2017 Nov 21. PubMed PMID: 29164301; PubMed Central PMCID: PMC5978912.
  6. 6. Crabb SJ, Martin K, Abab J, Ratcliffe I, Thornton R, Lineton B, Ellis M, Moody R, Stanton L, Galanopoulou A, Maishman T, Geldart T, Bayne M, Davies J, Lamb C, Popat S, Joffe JK, Nutting C, Chester J, Hartley A, Thomas G, Ottensmeier C, Huddart R, King E. COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss. Eur J Cancer. 2017 Dec;87:75-83.
  7. 7. Lee JY, Garcia-Murillas I, Cutts RJ, De Castro DG, Grove L, Hurley T, Wang F, Nutting C, Newbold K, Harrington K, Turner N, Bhide S. Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma. Br J Cancer. 2017 Sep 5;117(6):876-883.
  8. 8. Harrington K, Hall E, Hawkins M, Henry A, MacKay R, Maughan T, McDonald A, Nutting C, Oelfke U, Sebag-Montefiore D, Sharma RA, van Herk M, Faivre-Finn C; ART-NET Steering Committee. Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET). Clin Oncol (R Coll Radiol). 2017 Nov;29(11):707-710.
  9. 9. Richards TM, Hurley T, Grove L, Harrington KJ, Carpenter GH, Proctor GB, Nutting CM. The effect of parotid gland-sparing intensity-modulated radiotherapy on salivary composition, flow rate and xerostomia measures. Oral Dis. 2017 Oct;23(7):990-1000.
  10. 10. Mehanna H, McConkey CC, Rahman JK, Wong WL, Smith AF, Nutting C, Hartley AG, Hall P, Hulme C, Patel DK, Zeidler SV, Robinson M, Sanghera B, Fresco L, Dunn JA. PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technol Assess. 2017 Apr;21(17):1-122.
  11. 11. Panek R, Welsh L, Baker LCJ, Schmidt MA, Wong KH, Riddell AM, Koh DM, Dunlop A, Mcquaid D, d’Arcy JA, Bhide SA, Harrington KJ, Nutting CM, Hopkinson G, Richardson C, Box C, Eccles SA, Leach MO, Robinson SP, Newbold KL. Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI. Clin Cancer Res. 2017 Aug 1;23(15):4233-4241.
  12. 12. Wong KH, Panek R, Bhide SA, Nutting CM, Harrington KJ, Newbold KL. The emerging potential of magnetic resonance imaging in personalizing radiotherapy for head and neck cancer: an oncologist’s perspective. Br J Radiol. 2017 Mar;90(1071):20160768.
  13. 13. Petkar I, Bhide S, Newbold K, Harrington K, Nutting C. Dysphagia-optimised Intensity-modulated Radiotherapy Techniques in Pharyngeal Cancers: Is Anyone Going to Swallow it? Clin Oncol (R Coll Radiol). 2017 Jul;29(7):e110-e118.
  14. 14. Rupani A, Hughes OR, Watkinson J, Nutting CM, Thway K. Metastatic Papillary Thyroid Carcinoma With Adjacent BRAF (V600E)-Mutated Squamous Cell Carcinoma. Int J Surg Pathol. 2017 May;25(3):243-245.
  15. 15. Richards TM, Hurley T, Grove L, Harrington KJ, Carpenter GH, Proctor GB, Nutting CM. The effect of parotid gland-sparing intensity-modulated radiotherapy on salivary composition, flow rate and xerostomia measures. Oral Dis. 2017 Apr 23.
  16. 16. Dean JA, Welsh LC, Wong KH, Aleksic A, Dunne E, Islam MR, Patel A, Patel P, Petkar I, Phillips I, Sham J, Schick U, Newbold KL, Bhide SA, Harrington KJ, Nutting CM, Gulliford SL. Normal Tissue Complication Probability (NTCP) Modelling of Severe Acute Mucositis using a Novel Oral Mucosal Surface Organ at Risk. Clin Oncol (R Coll Radiol). 2017 Apr;29(4):263-273.
  17. 17. Mehanna H, McConkey CC, Rahman JK, Wong WL, Smith AF, Nutting C, Hartley AG, Hall P, Hulme C, Patel DK, Zeidler SV, Robinson M, Sanghera B, Fresco L, Dunn JA. PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technol Assess. 2017 Apr;21(17):1-122.
  18. 18. Panek R, Welsh L, Baker LCJ, Schmidt MA, Wong KH, Riddell AM, Koh DM, Dunlop A, Mcquaid D, d’Arcy JA, Bhide SA, Harrington KJ, Nutting CM, Hopkinson G, Richardson C, Box C, Eccles SA, Leach MO, Robinson SP, Newbold KL. Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI. Clin Cancer Res. 2017 Mar 17.
  19. 19. Wong KH, Panek R, Bhide SA, Nutting CM, Harrington KJ, Newbold KL. The emerging potential of magnetic resonance imaging in personalizing radiotherapy for head and neck cancer: an oncologist’s perspective. Br J Radiol. 2017 Mar;90(1071):20160768.
  20. 20. Guerreiro F, Burgos N, Dunlop A, Wong K, Petkar I, Nutting C, Harrington K, Bhide S, Newbold K, Dearnaley D, deSouza NM, Morgan VA, McClelland J, Nill S, Cardoso MJ, Ourselin S, Oelfke U, Knopf AC. Evaluation of a multi-atlas CT synthesis approach for MRI-only radiotherapy treatment planning. Phys Med. 2017 Mar;35:7-17.
  21. 21. Wong KH, Kuciejewska A, Sharabiani MT, Ng-Cheng-Hin B, Hoy S, Hurley T, Rydon J, Grove L, Santos A, Ryugenji M, Bhide SA, Nutting CM, Harrington KJ, Newbold KL. A randomised controlled trial of Caphosol mouthwash in management of radiation-induced mucositis in head and neck cancer. Radiother Oncol. 2017 Feb;122(2):207-211.
  22. 22. McLaughlin M, Barker HE, Khan AA, Pedersen M, Dillon M, Mansfield DC, Patel R, Kyula JN, Bhide SA, Newbold KL, Nutting CM, Harrington KJ. HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation. BMC Cancer. 2017 Jan 31;17(1):86.
  23. 23. Welsh L, Panek R, Riddell A, Wong K, Leach MO, Tavassoli M, Rahman D, Schmidt M, Hurley T, Grove L, Richards T, Koh DM, Nutting C, Harrington K, Newbold K, Bhide S. Blood transfusion during radical chemo-radiotherapy does not reduce tumour hypoxia in squamous cell cancer of the head and neck. Br J Cancer. 2017 Jan 3;116(1):28-35.
  24. 24. Gujral DM, Long M, Roe JW, Harrington KJ, Nutting CM. Standardisation of Target Volume Delineation for Carotid-sparing Intensity-modulated Radiotherapy in Early Glottis Cancer. Clin Oncol (R Coll Radiol). 2017 Jan;29(1):42-50.
  25. 25. Dillon MT, Barker HE, Pedersen M, Hafsi H, Bhide SA, Newbold KL, Nutting CM, McLaughlin M, Harrington KJ. Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei. Mol Cancer Ther. 2017 Jan;16(1):25-34.
  26. 26. Howard J, Masterson L, Dwivedi RC, Riffat F, Benson R, Jefferies S, Jani P, Tysome JR, Nutting C. Minimally invasive surgery versus radiotherapy/chemoradiotherapy for small-volume primary oropharyngeal carcinoma. Cochrane Database Syst Rev. 2016 Dec 11;12:CD010963.
  27. 27. Ness AR, Waylen A, Hurley K, Jeffreys M, Penfold C, Pring M, Leary SD, Allmark C, Toms S, Ring S, Peters TJ, Hollingworth W, Worthington H, Nutting C, Fisher S, Rogers SN, Thomas SJ; Head and Neck 5000 Study Team. Recruitment, response rates and characteristics of 5511 people enrolled in a prospective clinical cohort study: head and neck 5000. Clin Otolaryngol. 2016 Dec;41(6):804-809.
  28. 28. Wong KH, Panek R, Welsh L, Mcquaid D, Dunlop A, Riddell A, Murray I, Du Y, Chua S, Koh DM, Bhide S, Nutting C, Oyen WJ, Harrington K, Newbold KL. The Predictive Value of Early Assessment After 1 Cycle of Induction Chemotherapy with 18F-FDG PET/CT and Diffusion-Weighted MRI for Response to Radical Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma. J Nucl Med. 2016 Dec;57(12):1843-1850.
  29. 29. Schache AG, Powell NG, Cuschieri KS, Robinson M, Leary S, Mehanna H, Rapozo D, Long A, Cubie H, Junor E, Monaghan H, Harrington KJ, Nutting CM, Schick U, Lau AS, Upile N, Sheard J, Brougham K, West CM, Oguejiofor K, Thomas S, Ness AR, Pring M, Thomas GJ, King EV, McCance DJ, James JA, Moran M, Sloan P, Shaw RJ, Evans M, Jones TM. HPV-Related Oropharynx Cancer in the United Kingdom: An Evolution in the Understanding of Disease Etiology. Cancer Res. 2016 Nov 15;76(22):6598-6606.
  30. 30. Dean JA, Wong KH, Gay H, Welsh LC, Jones AB, Schick U, Oh JH, Apte A, Newbold KL, Bhide SA, Harrington KJ, Deasy JO, Nutting CM, Gulliford SL. Functional Data Analysis Applied to Modeling of Severe Acute Mucositis and Dysphagia Resulting From Head and Neck Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):820-831.
  31. 31. Panek R, Schmidt MA, Borri M, Koh DM, Riddell A, Welsh L, Dunlop A, Powell C, Bhide SA, Nutting CM, Harrington KJ, Newbold KL, Leach MO. Time-resolved angiography with stochastic trajectories for dynamic contrast-enhanced MRI in head and neck cancer: Are pharmacokinetic parameters affected? Med Phys. 2016 Nov;43(11):6024.
  32. 32. Fayette J, Wirth L, Oprean C, Udrea A, Jimeno A, Rischin D, Nutting C, Harari PM, Csoszi T, Cernea D, O’Brien P, Hanley WD, Kapp AV, Anderson M, Penuel E, McCall B, Pirzkall A, Vermorken JB. Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study). Front Oncol. 2016 Oct 31;6:232.
  33. 33. Petkar I, Rooney K, Roe JW, Patterson JM, Bernstein D, Tyler JM, Emson MA, Morden JP, Mertens K, Miles E, Beasley M, Roques T, Bhide SA, Newbold KL, Harrington KJ, Hall E, Nutting CM. DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer. BMC Cancer. 2016 Oct 6;16(1):770.
  34. 34. Bhide SA, Thway K, Lee J, Wong K, Clarke P, Newbold KL, Nutting CM, Harrington KJ. Delayed DNA double-strand break repair following platin-based chemotherapy predicts treatment response in head and neck squamous cell carcinoma. Br J Cancer. 2016 Sep 27;115(7):825-30.
  35. 35. Richards TM, Bhide SA, Miah AB, Del Rosario L, Bodla S, Thway K, Gujral DM, Rooney KP, Schick U, McGovern T, Grove L, Newbold KL, Harrington KJ, Nutting CM. Total Mucosal Irradiation with Intensity-modulated Radiotherapy in Patients with Head and Neck Carcinoma of Unknown Primary: A Pooled Analysis of Two Prospective Studies. Clin Oncol (R Coll Radiol). 2016 Sep;28(9):e77-84.
  36. 36. Miah AB, Gulliford SL, Morden J, Newbold KL, Bhide SA, Zaidi SH, Hall E, Harrington KJ, Nutting CM. Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy. Clin Oncol (R Coll Radiol). 2016 Sep;28(9):e69-76.
  37. 37. Barker HE, Patel R, McLaughlin M, Schick U, Zaidi S, Nutting CM, Newbold KL, Bhide S, Harrington KJ. CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy. Mol Cancer Ther. 2016 Sep;15(9):2042-54.
  38. 38. Miah AB, Bhide SA, Del Rosario L, Matthews J, Nicol R, Tanay MA, Gupta S, Zaidi SH, Newbold KL, Harrington KJ, Nutting CM. Induction Chemotherapy Followed by Chemo-intensity-modulated Radiotherapy for Locally Advanced Nasopharyngeal Cancer. Clin Oncol (R Coll Radiol). 2016 Aug;28(8):e61-7.
  39. 39. McQuaid D, Dunlop A, Nill S, Franzese C, Nutting CM, Harrington KJ, Newbold KL, Bhide SA. Evaluation of radiotherapy techniques for radical treatment of lateralised oropharyngeal cancers : Dosimetry and NTCP. Strahlenther Onkol. 2016 Aug;192(8):516-25.
  40. 40. Panek R, Welsh L, Dunlop A, Wong KH, Riddell AM, Koh DM, Schmidt MA, Doran S, Mcquaid D, Hopkinson G, Richardson C, Nutting CM, Bhide SA, Harrington KJ, Robinson SP, Newbold KL, Leach MO. Repeatability and sensitivity of T2* measurements in patients with head and neck squamous cell carcinoma at 3T. J Magn Reson Imaging. 2016 Jul;44(1):72-80.
  41. 41. Gujral DM, Cheung WK, Shah BN, Chahal NS, Bhattacharyya S, Hooper J, Senior R, Tang MX, Harrington KJ, Nutting CM. Contrast enhancement of carotid adventitial vasa vasorum as a biomarker of radiation-induced atherosclerosis. Radiother Oncol. 2016 Jul;120(1):63-8.
  42. 42. Dean JA, Wong KH, Welsh LC, Jones AB, Schick U, Newbold KL, Bhide SA, Harrington KJ, Nutting CM, Gulliford SL. Normal tissue complication probability (NTCP) modelling using spatial dose metrics and machine learning methods for severe acute oral mucositis resulting from head and neck radiotherapy. Radiother Oncol. 2016 Jul;120(1):21-7.
  43. 43. Shah BN, Gujral DM, Chahal NS, Harrington KJ, Nutting CM, Senior R. Plaque Neovascularization Is Increased in Human Carotid Atherosclerosis Related to Prior Neck Radiotherapy: A Contrast-Enhanced Ultrasound Study. JACC Cardiovasc Imaging. 2016 Jun;9(6):668-75.
  44. 44. Gujral DM, Shah BN, Chahal NS, Bhattacharyya S, Senior R, Harrington KJ, Nutting CM. Do traditional risk stratification models for cerebrovascular events apply in irradiated head and neck cancer patients? QJM. 2016 Jun;109(6):383-9.
  45. 45. Dwivedi RC, St Rose S, Chisholm EJ, Clarke PM, Kerawala CJ, Nutting CM, Rhys-Evans PH, Kazi R, Harrington KJ. Acoustic parameters of speech: Lack of correlation with perceptual and questionnaire-based speech evaluation in patients with oral and oropharyngeal cancer treated with primary surgery. Head Neck. 2016 May;38(5):670-6.
  46. 46. Nutting C. Radiotherapy in head and neck cancer management: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016 May;130(S2):S66-S67.
  47. 47. Mehanna H, Wong WL, McConkey CC, Rahman JK, Robinson M, Hartley AG, Nutting C, Powell N, Al-Booz H, Robinson M, Junor E, Rizwanullah M, von Zeidler SV, Wieshmann H, Hulme C, Smith AF, Hall P, Dunn J; PET-NECK Trial Management Group. PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer. N Engl J Med. 2016 Apr 14;374(15):1444-54.
  48. 48. Roe JW, Carding PN, Drinnan MJ, Harrington KJ, Nutting CM. Swallowing performance and tube feeding status in patients treated with parotid-sparing intensity-modulated radiotherapy for head and neck cancer. Head Neck. 2016 Apr;38 Suppl 1:E1436-44.
  49. 49. Dean JA, Welsh LC, McQuaid D, Wong KH, Aleksic A, Dunne E, Islam MR, Patel A, Patel P, Petkar I, Phillips I, Sham J, Newbold KL, Bhide SA, Harrington KJ, Gulliford SL, Nutting CM. Assessment of fully-automated atlas-based segmentation of novel oral mucosal surface organ-at-risk. Radiother Oncol. 2016 Apr;119(1):166-71.
  50. 50. Gujral DM, Shah BN, Chahal NS, Bhattacharyya S, Senior R, Harrington KJ, Nutting CM. Arterial Stiffness as a Biomarker of Radiation-Induced Carotid Atherosclerosis. Angiology. 2016 Mar;67(3):266-71.
  51. 51. Gujral DM, Shah BN, Chahal NS, Bhattacharyya S, Hooper J, Senior R, Harrington KJ, Nutting CM. Carotid intima-medial thickness as a marker of radiation-induced carotid atherosclerosis. Radiother Oncol. 2016 Feb;118(2):323-9.
  52. 52. Gujral DM, Shah BN, Bhattacharyya S, Senior R, Harrington KJ, Nutting CM. Contrast-enhanced ultrasound to assess plaque neovascularization in irradiated carotid arteries. Int J Cardiol. 2016 Jan 1;202:3-4.
  53. 53. Dunlop A, McQuaid D, Nill S, Murray J, Poludniowski G, Hansen VN, Bhide S, Nutting C, Harrington K, Newbold K, Oelfke U. Comparison of CT number calibration techniques for CBCT-based dose calculation. Strahlenther Onkol. 2015 Dec;191(12):970-8.
  54. 54. Otter S, Schick U, Gulliford S, Lal P, Franceschini D, Newbold K, Nutting C, Harrington K, Bhide S. Evaluation of the Risk of Grade 3 Oral and Pharyngeal Dysphagia Using Atlas-Based Method and Multivariate Analyses of Individual Patient Dose Distributions. Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):507-15.
  55. 55. Brouwer CL, Steenbakkers RJ, Bourhis J, Budach W, Grau C, Grégoire V, van Herk M, Lee A, Maingon P, Nutting C, O’Sullivan B, Porceddu SV, Rosenthal DI, Sijtsema NM, Langendijk JA. CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines. Radiother Oncol. 2015 Oct;117(1):83-90.
  56. 56. Borri M, Schmidt MA, Powell C, Koh DM, Riddell AM, Partridge M, Bhide SA, Nutting CM, Harrington KJ, Newbold KL, Leach MO. Characterizing Heterogeneity within Head and Neck Lesions Using Cluster Analysis of Multi-Parametric MRI Data. PLoS One. 2015 Sep 23;10(9):e0138545.
  57. 57. Evans CM, Burnet NG, Hall E, Huddart RA, Nutting CM, Coles CE. The Radiotherapy Clinical Trial Research Landscape in the UK Between 2004 and 2013: A Cross-sectional Analysis. Clin Oncol (R Coll Radiol). 2015 Sep;27(9):491-4.
  58. 58. Aitken K, Tree A, Thomas K, Nutting C, Hawkins M, Tait D, Mandeville H, Ahmed M, Lalondrelle S, Miah A, Taylor A, Ross G, Khoo V, van As N. Initial UK Experience of Stereotactic Body Radiotherapy for Extracranial Oligometastases: Can We Change the Therapeutic Paradigm? Clin Oncol (R Coll Radiol). 2015 Jul;27(7):411-9.
  59. 59. Cheung WK, Gujral DM, Shah BN, Chahal NS, Bhattacharyya S, Cosgrove DO, Eckersley RJ, Harrington KJ, Senior R, Nutting CM, Tang MX. Attenuation Correction and Normalisation for Quantification of Contrast Enhancement in Ultrasound Images of Carotid Arteries. Ultrasound Med Biol. 2015 Jul;41(7):1876-83.
  60. 60. Welsh L, Panek R, McQuaid D, Dunlop A, Schmidt M, Riddell A, Koh DM, Doran S, Murray I, Du Y, Chua S, Hansen V, Wong KH, Dean J, Gulliford S, Bhide S, Leach MO, Nutting C, Harrington K, Newbold K. Prospective, longitudinal, multi-modal functional imaging for radical chemo-IMRT treatment of locally advanced head and neck cancer: the INSIGHT study. Radiat Oncol. 2015 May 15;10:112.
  61. 61. Dean JA, Welsh LC, Gulliford SL, Harrington KJ, Nutting CM. A novel method for delineation of oral mucosa for radiotherapy dose-response studies. Radiother Oncol. 2015 Apr;115(1):63-6.
  62. 62. Dunlop A, Welsh L, McQuaid D, Dean J, Gulliford S, Hansen V, Bhide S, Nutting C, Harrington K, Newbold K. Brain-sparing methods for IMRT of head and neck cancer. PLoS One. 2015 Mar 17;10(3):e0120141.
  63. 63. Miah AB, Schick U, Bhide SA, Guerrero-Urbano MT, Clark CH, Bidmead AM, Bodla S, Del Rosario L, Thway K, Wilson P, Newbold KL, Harrington KJ, Nutting CM. A phase II trial of induction chemotherapy and chemo-IMRT for head and neck squamous cell cancers at risk of bilateral nodal spread: the application of a bilateral superficial lobe parotid-sparing IMRT technique and treatment outcomes. Br J Cancer. 2015 Jan 6;112(1):32-8.
  64. 64. Ness AR, Waylen A, Hurley K, Jeffreys M, Penfold C, Pring M, Leary S, Allmark C, Toms S, Ring S, Peters TJ, Hollingworth W, Worthington H, Nutting C, Fisher S, Rogers SN, Thomas SJ; Head and Neck 5000 Study Team. Establishing a large prospective clinical cohort in people with head and neck cancer as a biomedical resource: head and neck 5000. BMC Cancer. 2014 Dec 17;14:973.
  65. 65. Welsh LC, Dunlop AW, McGovern T, McQuaid D, Dean JA, Gulliford SL, Bhide SA, Harrington KJ, Nutting CM, Newbold KL. Neurocognitive function after (chemo)-radiotherapy for head and neck cancer. Clin Oncol (R Coll Radiol). 2014 Dec;26(12):765-75.
  66. 66. Ruzsa A, Sen M, Evans M, Lee LW, Hideghety K, Rottey S, Klimak P, Holeckova P, Fayette J, Csoszi T, Erfan J, Forssmann U, Goddemeier T, Bexon A, Nutting C; NA EMD 1201081 Study Group. Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Invest New Drugs. 2014 Dec;32(6):1278-84.
  67. 67. Roe JW, Drinnan MJ, Carding PN, Harrington KJ, Nutting CM. Patient-reported outcomes following parotid-sparing intensity-modulated radiotherapy for head and neck cancer. How important is dysphagia? Oral Oncol. 2014 Dec;50(12):1182-7.
  68. 68. Gujral DM, Miah AB, Bodla S, Richards TM, Welsh L, Schick U, Powell CJ, Clark CH, Bidmead MA, Grove L, Guerrero-Urbano T, Bhide SA, Newbold KL, Harrington KJ, Nutting CM. Final long-term results of a phase I/II study of dose-escalated intensity-modulated radiotherapy for locally advanced laryngo-hypopharyngeal cancers. Oral Oncol. 2014 Nov;50(11):1089-97.
  69. 69. Barbieri M, Weatherly HL, Ara R, Basarir H, Sculpher M, Adams R, Ahmed H, Coles C, Guerrero-Urbano T, Nutting C, Powell M. What is the quality of economic evaluations of non-drug therapies? A systematic review and critical appraisal of economic evaluations of radiotherapy for cancer. Appl Health Econ Health Policy. 2014 Oct;12(5):497-510.
  70. 70. Irune E, Dwivedi RC, Nutting CM, Harrington KJ. Treatment-related dysgeusia in head and neck cancer patients. Cancer Treat Rev. 2014 Oct;40(9):1106-17.
  71. 71. Lynch J, Lal P, Schick U, Nutting CM, Newbold K, Harrington K, Bhide S. Multiple cervical lymph node involvement and extra-capsular extension predict for contralateral nodal recurrence after ipsilateral radiotherapy for squamous cell carcinoma of the tonsil. Oral Oncol. 2014 Sep;50(9):901-6.
  72. 72. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Peña C, Molnár I, Schlumberger MJ; DECISION investigators. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014 Jul 26;384(9940):319-28.
  73. 73. Aitken KL, Tait DM, Nutting CM, Khabra K, Hawkins MA. Risk-adapted strategy partial liver irradiation for the treatment of large volume metastatic liver disease. Acta Oncol. 2014 May;53(5):702-6.
  74. 74. Powell C, Schick U, Morden JP, Gulliford SL, Miah AB, Bhide S, Newbold K, Harrington KJ, Nutting CM. Fatigue during chemoradiotherapy for nasopharyngeal cancer and its relationship to radiation dose distribution in the brain. Radiother Oncol. 2014 Mar;110(3):416-21.
  75. 75. Gujral DM, Shah BN, Chahal NS, Senior R, Harrington KJ, Nutting CM. Clinical features of radiation-induced carotid atherosclerosis. Clin Oncol (R Coll Radiol). 2014 Feb;26(2):94-102.
  76. 76. Gujral DM, Piercy D, Morden JP, Emson M, Hall E, Miah AB, Bhide SA, Newbold KL, Harrington KJ, Nutting CM. Current attitudes of head and neck oncologists in the United Kingdom to induction chemotherapy for locally advanced head and neck cancer: a survey of centres participating in a national randomised controlled trial. Oral Oncol. 2014 Feb;50(2):141-6.
  77. 77. Grégoire V, Ang K, Budach W, Grau C, Hamoir M, Langendijk JA, Lee A, Le QT, Maingon P, Nutting C, O’Sullivan B, Porceddu SV, Lengele B. Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiother Oncol. 2014 Jan;110(1):172-81.
  78. 78. Gujral DM, Chahal N, Senior R, Harrington KJ, Nutting CM. Radiation-induced carotid artery atherosclerosis. Radiother Oncol. 2014 Jan;110(1):31-8.
  79. 79. Wilkins AC, Rosenfelder N, Schick U, Gupta S, Thway K, Nutting CM, Harrington KJ, Newbold K, Bhide SA. Equivalence of cisplatin and carboplatin-based chemoradiation for locally advanced squamous cell carcinoma of the head and neck: a matched-pair analysis. Oral Oncol. 2013 Jun;49(6):615-9.
  80. 80. Welsh L, Powell C, Pratt B, Harrington K, Nutting C, Harmer C, Newbold K. Long-term outcomes following low-dose radioiodide ablation for differentiated thyroid cancer. J Clin Endocrinol Metab. 2013 May;98(5):1819-25.
  81. 81. Popat S, Wotherspoon A, Nutting CM, Gonzalez D, Nicholson AG, O’Brien M. Transformation to “high grade” neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma. Lung Cancer. 2013 Apr;80(1):1-4.
  82. 82. Miah AB, Gulliford SL, Clark CH, Bhide SA, Zaidi SH, Newbold KL, Harrington KJ, Nutting CM. Dose-response analysis of parotid gland function: what is the best measure of xerostomia? Radiother Oncol. 2013 Mar;106(3):341-5.
  83. 83. Miah AB, Gulliford SL, Bhide SA, Zaidi SH, Newbold KL, Harrington KJ, Nutting CM. The effect of concomitant chemotherapy on parotid gland function following head and neck IMRT. Radiother Oncol. 2013 Mar;106(3):346-51.
  84. 84. Tree AC, Khoo VS, Eeles RA, Ahmed M, Dearnaley DP, Hawkins MA, Huddart RA, Nutting CM, Ostler PJ, van As NJ. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013 Jan;14(1):e28-37.
  85. 85. Powell C, Schmidt M, Borri M, Koh DM, Partridge M, Riddell A, Cook G, Bhide SA, Nutting CM, Harrington KJ, Newbold KL. Changes in functional imaging parameters following induction chemotherapy have important implications for individualised patient-based treatment regimens for advanced head and neck cancer. Radiother Oncol. 2013 Jan;106(1):112-7.
  86. 86. Hughes C, Homer J, Bradley P, Nutting C, Ness A, Persson M, Jeffreys M, Waylen A, Leary S, Thomas S. An evaluation of current services available for people diagnosed with head and neck cancer in the UK (2009-2010). Clin Oncol (R Coll Radiol). 2012 Dec;24(10):e187-92.
  87. 87. Burnet NG, Billingham LJ, Chan CS, Hall E, Macdougall J, Mackay RI, Maughan TS, Nutting CM, Staffurth JN, Illidge TM; National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group Executive Group. Methodological considerations in the evaluation of radiotherapy technologies. Clin Oncol (R Coll Radiol). 2012 Dec;24(10):707-9.
  88. 88. Dwivedi RC, St Rose S, Chisholm EJ, Georgalas C, Bisase B, Amen F, Kerawala CJ, Clarke PM, Nutting CM, Rhys-Evans PH, Harrington KJ, Kazi R. Evaluation of swallowing by Sydney Swallow Questionnaire (SSQ) in oral and oropharyngeal cancer patients treated with primary surgery. Dysphagia. 2012 Dec;27(4):491-7.
  89. 89. Newbold KL, Bhide S, Convery H, Harrington KJ, Nutting CM. Prospective intra-patient evaluation of a shoulder retraction device for radiotherapy in head and neck cancer. Med Dosim. 2012 Autumn;37(3):293-5.
  90. 90. Brose MS, Smit J, Capdevila J, Elisei R, Nutting C, Pitoia F, Robinson B, Schlumberger M, Shong YK, Takami H. Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma. Expert Rev Anticancer Ther. 2012 Sep;12(9):1137-47.
  91. 91. Gulliford SL, Miah AB, Brennan S, McQuaid D, Clark CH, Partridge M, Harrington KJ, Morden JP, Hall E, Nutting CM. Dosimetric explanations of fatigue in head and neck radiotherapy: an analysis from the PARSPORT Phase III trial. Radiother Oncol. 2012 Aug;104(2):205-12.
  92. 92. Murray JR, Williams GR, Harrington KJ, Newbold K, Nutting CM. Rising thyroglobulin tumour marker during pregnancy in a thyroid cancer patient: no cause for alarm? Clin Endocrinol (Oxf). 2012 Jul;77(1):155-7.
  93. 93. Nutting CM. Intensity Modulated Radiotherapy (IMRT) in head and neck cancers – an overview. Gulf J Oncolog. 2012 Jul;(12):17-26.
  94. 94. Dwivedi RC, St Rose S, Chisholm EJ, Bisase B, Amen F, Nutting CM, Clarke PM, Kerawala CJ, Rhys-Evans PH, Harrington KJ, Kazi R. Evaluation of speech outcomes using English version of the Speech Handicap Index in a cohort of head and neck cancer patients. Oral Oncol. 2012 Jun;48(6):547-53.
  95. 95. Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012 May 3;366(18):1674-85.
  96. 96. Bhide SA, Newbold KL, Harrington KJ, Nutting CM. Clinical evaluation of intensity-modulated radiotherapy for head and neck cancers. Br J Radiol. 2012 May;85(1013):487-94.
  97. 97. Spencer CR, Skilbeck CJ, Thway K, Nutting CM. Lymphoepithelial carcinoma of the parotid gland: a rare neck lump. JRSM Short Rep. 2012 May;3(5):28.
  98. 98. Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, Newbold K, Gore ME, Larkin J, Syrigos KN, Coffey M, Thompson B, Mettinger K, Vile RG, Pandha HS, Hall GD, Melcher AA, Chester J, Harrington KJ. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res. 2012 Apr 1;18(7):2080-9.
  99. 99. Mallick U, Harmer C, Hackshaw A, Moss L; IoN Trial Management Group. Iodine or Not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo. Clin Oncol (R Coll Radiol). 2012 Apr;24(3):159-61.
  100. 100. Dwivedi RC, Chisholm EJ, Khan AS, Harris NJ, Bhide SA, St Rose S, Kerawala CJ, Clarke PM, Nutting CM, Rhys-Evans PH, Harrington KJ, Kazi R. An exploratory study of the influence of clinico-demographic variables on swallowing and swallowing-related quality of life in a cohort of oral and oropharyngeal cancer patients treated with primary surgery. Eur Arch Otorhinolaryngol. 2012 Apr;269(4):1233-9.
  101. 101. Roe JW, Carding PN, Rhys-Evans PH, Newbold KL, Harrington KJ, Nutting CM. Assessment and management of dysphagia in patients with head and neck cancer who receive radiotherapy in the United Kingdom – a web-based survey. Oral Oncol. 2012 Apr;48(4):343-8.
  102. 102. Buettner F, Miah AB, Gulliford SL, Hall E, Harrington KJ, Webb S, Partridge M, Nutting CM. Novel approaches to improve the therapeutic index of head and neck radiotherapy: an analysis of data from the PARSPORT randomised phase III trial. Radiother Oncol. 2012 Apr;103(1):82-7.
  103. 103. Bhide SA, Gulliford S, Schick U, Miah A, Zaidi S, Newbold K, Nutting CM, Harrington KJ. Dose-response analysis of acute oral mucositis and pharyngeal dysphagia in patients receiving induction chemotherapy followed by concomitant chemo-IMRT for head and neck cancer. Radiother Oncol. 2012 Apr;103(1):88-91.
  104. 104. Dwivedi RC, St Rose S, Chisholm EJ, Youssefi P, Hassan MS, Khan AS, Elmiyeh B, Kerawala CJ, Clarke PM, Nutting CM, Rhys-Evans PH, Harrington KJ, Kazi R. Evaluation of factors affecting post-treatment quality of life in oral and oropharyngeal cancer patients primarily treated with curative surgery: an exploratory study. Eur Arch Otorhinolaryngol. 2012 Feb;269(2):591-9.
  105. 105. Miah AB, Bhide SA, Guerrero-Urbano MT, Clark C, Bidmead AM, St Rose S, Barbachano Y, A’hern R, Tanay M, Hickey J, Nicol R, Newbold KL, Harrington KJ, Nutting CM. Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers. Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):539-47.
  106. 106. Schick U, Gujral DM, Richards TM, Harrington KJ, Nutting CM. Zalutumumab in head and neck cancer. Expert Opin Biol Ther. 2012 Jan;12(1):119-25.
  107. 107. Dwivedi RC, Rose SS, Chisholm EJ, Kerawala CJ, Clarke PM, Nutting CM, Rhys-Evans PH, Harrington KJ, Kazi R. Development and validation of first-ever speech-specific perceptual speech evaluation tool for patients with head and neck cancer: the London speech evaluation (LSE) scale. Head Neck. 2012 Jan;34(1):94-103.
  108. 108. Bhide SA, Ahmed M, Newbold K, Harrington KJ, Nutting CM. The role of intensity modulated radiotherapy in advanced oral cavity carcinoma. J Cancer Res Ther. 2012 Jan;8 Suppl 1:S67-71.
  109. 109. Zaidi S, McLaughlin M, Bhide SA, Eccles SA, Workman P, Nutting CM, Huddart RA, Harrington KJ. The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage. PLoS One. 2012;7(4):e35436. doi: 10.1371/journal.pone.0035436. Epub 2012 Apr 16. PubMed PMID: 22523597; PubMed Central PMCID: PMC3327673.
  110. 110. Nutting CM, Scully C. Oral cancer: comprehending the condition, causes, controversies, control and consequences. 12. Radiotherapy and chemotherapy. Dent Update. 2011 Dec;38(10):717-9.
  111. 111. Dwivedi RC, Dwivedi RC, Kazi R, Kanwar N, Nutting CM, Harrington KJ, Rhys-Evans PH. Should the treatment paradigms for oral and oropharyngeal cancers be changed now: the role of human papilloma virus? ANZ J Surg. 2011 Sep;81(9):581-3.
  112. 112. Del Campo JM, Hitt R, Sebastian P, Carracedo C, Lokanatha D, Bourhis J, Temam S, Cupissol D, De Raucourt D, Maroudias N, Nutting CM, Compton N, Midwinter D, Downie L, Biswas-Baldwin N, El-Hariry I, Harrington KJ. Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer. 2011 Aug 23;105(5):618-27.
  113. 113. Harrington KJ, Billingham LJ, Brunner TB, Burnet NG, Chan CS, Hoskin P, Mackay RI, Maughan TS, Macdougall J, McKenna WG, Nutting CM, Oliver A, Plummer R, Stratford IJ, Illidge T. Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. Br J Cancer. 2011 Aug 23;105(5):628-39.
  114. 114. Brose MS, Nutting CM, Sherman SI, Shong YK, Smit JW, Reike G, Chung J, Kalmus J, Kappeler C, Schlumberger M. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer. 2011 Aug 11;11:349.
  115. 115. Ahmed M, Barbachano Y, Riddell A, Hickey J, Newbold KL, Viros A, Harrington KJ, Marais R, Nutting CM. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol. 2011 Aug;165(2):315-22.
  116. 116. Schick U, Richards T, Miah A, Nutting CM. Stereotactic body radiotherapy: overview of the 2010 Royal College of Radiologists’ annual scientific meeting. Clin Oncol (R Coll Radiol). 2011 Apr;23(3):165-7.
  117. 117. Sayed SI, Dwivedi RC, Katna R, Garg A, Pathak KA, Nutting CM, Rhys-Evans P, Harrington KJ, Kazi R. Implications of understanding cancer stem cell (CSC) biology in head and neck squamous cell cancer. Oral Oncol. 2011 Apr;47(4):237-43.
  118. 118. Dwivedi RC, St Rose S, Roe JW, Chisholm E, Elmiyeh B, Nutting CM, Clarke PM, Kerawala CJ, Rhys-Evans PH, Harrington KJ, Kazi R. First report on the reliability and validity of speech handicap index in native English-speaking patients with head and neck cancer. Head Neck. 2011 Mar;33(3):341-8.
  119. 119. Mehanna H, Paleri V, West CM, Nutting C. Head and neck cancer-part 1: epidemiology, presentation, and preservation. Clin Otolaryngol. 2011 Feb;36(1):65-8.
  120. 120. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M, Adab F, Jefferies SJ, Scrase C, Yap BK, A’Hern RP, Sydenham MA, Emson M, Hall E; PARSPORT trial management group. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011 Feb;12(2):127-36.
  121. 121. Shaw R, Forner L, Butterworth C, Jansen E, Hillerup S, Nutting C, Overgaard J. Randomised controlled trials in HBO: “A call to arms” for HOPON & DAHANCA-21. Br J Oral Maxillofac Surg. 2011 Jan;49(1):76-7.
  122. 122. Powell C, Mikropoulos C, Kaye SB, Nutting CM, Bhide SA, Newbold K, Harrington KJ. Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers. Cancer Treat Rev. 2010 Nov;36(7):566-75.
  123. 123. Scott-Brown M, Miah A, Harrington K, Nutting C. Evidence-based review: quality of life following head and neck intensity-modulated radiotherapy. Radiother Oncol. 2010 Nov;97(2):249-57.
  124. 124. Maughan TS, Illidge TM, Hoskin P, McKenna WG, Brunner TB, Stratford IJ, Harrington KJ, Plummer R, Billingham LJ, Nutting C, Burnet NG, Mackay RI, Oliver A, Young C, Chan CS; NCRI Clinical and Translational Radiotherapy Research Working Group. Radiotherapy research priorities for the UK. Clin Oncol (R Coll Radiol). 2010 Oct;22(8):707-9.
  125. 125. Roe JW, Carding PN, Dwivedi RC, Kazi RA, Rhys-Evans PH, Harrington KJ, Nutting CM. Swallowing outcomes following Intensity Modulated Radiation Therapy (IMRT) for head & neck cancer – a systematic review. Oral Oncol. 2010 Oct;46(10):727-33.
  126. 126. Bhide SA, Gulliford S, Fowler J, Rosenfelder N, Newbold K, Harrington KJ, Nutting CM. Characteristics of response of oral and pharyngeal mucosa in patients receiving chemo-IMRT for head and neck cancer using hypofractionated accelerated radiotherapy. Radiother Oncol. 2010 Oct;97(1):86-91.
  127. 127. Mehanna H, West CM, Nutting C, Paleri V. Head and neck cancer–Part 2: Treatment and prognostic factors. BMJ. 2010 Sep 28;341:c4690.
  128. 128. Mehanna H, Paleri V, West CM, Nutting C. Head and neck cancer–Part 1: Epidemiology, presentation, and prevention. BMJ. 2010 Sep 20;341:c4684.
  129. 129. Hingorani M, White CL, Zaidi S, Pandha HS, Melcher AA, Bhide SA, Nutting CM, Syrigos KN, Vile RG, Vassaux G, Harrington KJ. Therapeutic effect of sodium iodide symporter gene therapy combined with external beam radiotherapy and targeted drugs that inhibit DNA repair. Mol Ther. 2010 Sep;18(9):1599-605.
  130. 130. Harrington KJ, Hingorani M, Tanay MA, Hickey J, Bhide SA, Clarke PM, Renouf LC, Thway K, Sibtain A, McNeish IA, Newbold KL, Goldsweig H, Coffin R, Nutting CM. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res. 2010 Aug 1;16(15):4005-15.
  131. 131. Powell C, Newbold K, Harrington KJ, Bhide SA, Nutting CM. External beam radiotherapy for differentiated thyroid cancer. Clin Oncol (R Coll Radiol). 2010 Aug;22(6):456-63.
  132. 132. Bhide SA, Kazi R, Newbold K, Harrington KJ, Nutting CM. The role of intensity-modulated radiotherapy in head and neck cancer. Indian J Cancer. 2010 Jul-Sep;47(3):267-73.
  133. 133. Dandekar P, Partridge M, Kazi R, Nutting C, Harrington K, Newbold K. Challenges in integrating 18FDG PET-CT into radiotherapy planning of head and neck cancer. Indian J Cancer. 2010 Jul-Sep;47(3):260-6.
  134. 134. Harrington KJ, Kazi R, Bhide SA, Newbold K, Nutting CM. Novel therapeutic approaches to squamous cell carcinoma of the head and neck using biologically targeted agents. Indian J Cancer. 2010 Jul-Sep;47(3):248-59.
  135. 135. Khan A, Smellie J, Nutting C, Harrington K, Newbold K. Familial nonmedullary thyroid cancer: a review of the genetics. Thyroid. 2010 Jul;20(7):795-801.
  136. 136. Harrington KJ, Karapanagiotou EM, Roulstone V, Twigger KR, White CL, Vidal L, Beirne D, Prestwich R, Newbold K, Ahmed M, Thway K, Nutting CM, Coffey M, Harris D, Vile RG, Pandha HS, Debono JS, Melcher AA. Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res. 2010 Jun 1;16(11):3067-77.
  137. 137. Bhide SA, Nutting CM. Advances in radiotherapy for head and neck cancer. Oral Oncol. 2010 Jun;46(6):439-41.
  138. 138. Bhide SA, Nutting CM. Advances in chemotherapy for head and neck cancer. Oral Oncol. 2010 Jun;46(6):436-8.
  139. 139. Harrington KJ, Nutting CM. Bravo for PRAVO. Lancet Oncol. 2010 May;11(5):407-8.
  140. 140. Dwivedi RC, Kazi R, Agrawal N, Chisholm E, St Rose S, Elmiyeh B, Rennie C, Pepper C, Clarke PM, Kerawala CJ, Rhys-Evans PH, Harrington KJ, Nutting CM. Comprehensive review of small bowel metastasis from head and neck squamous cell carcinoma. Oral Oncol. 2010 May;46(5):330-5.
  141. 141. Bhide SA, Nutting CM. Recent advances in radiotherapy. BMC Med. 2010 Apr 28;8:25.
  142. 142. Guerrero Urbano T, Khoo V, Staffurth J, Norman A, Buffa F, Jackson A, Adams E, Hansen V, Clark C, Miles E, McNair H, Nutting C, Parker C, Eeles R, Huddart R, Horwich A, Dearnaley DP. Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study. Clin Oncol (R Coll Radiol). 2010 Apr;22(3):236-44.
  143. 143. Bhide SA, Davies M, Burke K, McNair HA, Hansen V, Barbachano Y, El-Hariry IA, Newbold K, Harrington KJ, Nutting CM. Weekly volume and dosimetric changes during chemoradiotherapy with intensity-modulated radiation therapy for head and neck cancer: a prospective observational study. Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1360-8.
  144. 144. Dwivedi RC, St Rose S, Roe JW, Khan AS, Pepper C, Nutting CM, Clarke PM, Kerawala CJ, Rhys-Evans PH, Harrington KJ, Kazi R. Validation of the Sydney Swallow Questionnaire (SSQ) in a cohort of head and neck cancer patients. Oral Oncol. 2010 Apr;46(4):e10-4.
  145. 145. Bhide SA, Newbold KL, Harrington KJ, Nutting CM. Combined chemotherapy and intensity-modulated radiotherapy for the treatment of head and neck cancers. Expert Rev Anticancer Ther. 2010 Mar;10(3):297-300.
  146. 146. Ahmed M, Schmidt M, Sohaib A, Kong C, Burke K, Richardson C, Usher M, Brennan S, Riddell A, Davies M, Newbold K, Harrington KJ, Nutting CM. The value of magnetic resonance imaging in target volume delineation of base of tongue tumours–a study using flexible surface coils. Radiother Oncol. 2010 Feb;94(2):161-7.
  147. 147. Sayed SI, Manikantan K, Khode S, Jagade M, Kasbekar VG, Shah R, Palav RS, Nutting CM, Harrington KJ, Rhys-Evans P, Kazi R. Tracheo-oesophageal party wall thickness in laryngectomised patients in India: implications for surgical voice restoration. J Surg Oncol. 2010 Jan 1;101(1):78-83.
  148. 148. Manikantan K, Khode S, Sayed SI, Roe J, Nutting CM, Rhys-Evans P, Harrington KJ, Kazi R. Dysphagia in head and neck cancer. Cancer Treat Rev. 2009 Dec;35(8):724-32.
  149. 149. Manikantan K, Khode S, Dwivedi RC, Palav R, Nutting CM, Rhys-Evans P, Harrington KJ, Kazi R. Making sense of post-treatment surveillance in head and neck cancer: when and what of follow-up. Cancer Treat Rev. 2009 Dec;35(8):744-53.
  150. 150. Bhide SA, Miah AB, Harrington KJ, Newbold KL, Nutting CM. Radiation-induced xerostomia: pathophysiology, prevention and treatment. Clin Oncol (R Coll Radiol). 2009 Dec;21(10):737-44.
  151. 151. Bhide SA, Gulliford S, Kazi R, El-Hariry I, Newbold K, Harrington KJ, Nutting CM. Correlation between dose to the pharyngeal constrictors and patient quality of life and late dysphagia following chemo-IMRT for head and neck cancer. Radiother Oncol. 2009 Dec;93(3):539-44.
  152. 152. Manikantan K, Sayed SI, Syrigos KN, Rhys-Evans P, Nutting CM, Harrington KJ, Kazi R. Challenges for the future modifications of the TNM staging system for head and neck cancer: case for a new computational model? Cancer Treat Rev. 2009 Nov;35(7):639-44.
  153. 153. Ahmed M, Hansen VN, Harrington KJ, Nutting CM. Reducing the risk of xerostomia and mandibular osteoradionecrosis: the potential benefits of intensity modulated radiotherapy in advanced oral cavity carcinoma. Med Dosim. 2009Fall;34(3):217-24.
  154. 154. Clark CH, Hansen VN, Chantler H, Edwards C, James HV, Webster G, Miles EA, Guerrero Urbano MT, Bhide SA, Bidmead AM, Nutting CM; PARSPORT Trial Management Group. Dosimetry audit for a multi-centre IMRT head and neck trial. Radiother Oncol. 2009 Oct;93(1):102-8.
  155. 155. Dwivedi RC, Kazi RA, Agrawal N, Nutting CM, Clarke PM, Kerawala CJ, Rhys-Evans PH, Harrington KJ. Evaluation of speech outcomes following treatment of oral and oropharyngeal cancers. Cancer Treat Rev. 2009 Aug;35(5):417-24.
  156. 156. Sayed SI, Elmiyeh B, Rhys-Evans P, Syrigos KN, Nutting CM, Harrington KJ, Kazi R. Quality of life and outcomes research in head and neck cancer: a review of the state of the discipline and likely future directions. Cancer Treat Rev. 2009 Aug;35(5):397-402.
  157. 157. Kazi R, Nutting CM, Rhys-Evans P, Harrington KJ. A short perspective on the surgical restoration of alaryngeal speech. South Med J. 2009 Aug;102(8):838-40.
  158. 158. Nutting CM, van Herpen CM, Miah AB, Bhide SA, Machiels JP, Buter J, Kelly C, de Raucourt D, Harrington KJ. Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2009 Jul;20(7):1275-9.
  159. 159. Clark CH, Miles EA, Urbano MT, Bhide SA, Bidmead AM, Harrington KJ, Nutting CM; UK PARSPORT Trial Management Group collaborators. Pre-trial quality assurance processes for an intensity-modulated radiation therapy (IMRT) trial: PARSPORT, a UK multicentre Phase III trial comparing conventional radiotherapy and parotid-sparing IMRT for locally advanced head and neck cancer. Br J Radiol. 2009 Jul;82(979):585-94.
  160. 160. Dwivedi RC, Nutting CM, Rhys-Evans P, Harrington KJ, Kazi R. Future perspectives for health related quality of life (HRQOL) studies in head and neck cancer. G Ital Med Lav Ergon. 2009 Jul-Sep;31(3 Suppl B):B17-20.
  161. 161. Kazi R, Nutting CM, Rhys-Evans P, Harrington KJ. Significance and prognostic impact of co-morbidity in head and neck cancer. J Cancer Res Ther. 2009 Jul-Sep;5(3):145-7.
  162. 162. Bhide SA, Miah A, Barbachano Y, Harrington KJ, Newbold K, Nutting CM. Radical radiotherapy for treatment of malignant parotid tumours: a single centre experience 1995-2005. Br J Oral Maxillofac Surg. 2009 Jun;47(4):284-9.
  163. 163. Dandekar P, Harmer C, Barbachano Y, Rhys-Evans P, Harrington K, Nutting C, Newbold K. Hyperfractionated Accelerated Radiotherapy (HART) for anaplastic thyroid carcinoma: toxicity and survival analysis. Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):518-21.
  164. 164. Syrigos KN, Karachalios D, Karapanagiotou EM, Nutting CM, Manolopoulos L, Harrington KJ. Head and neck cancer in the elderly: an overview on the treatment modalities. Cancer Treat Rev. 2009 May;35(3):237-45.
  165. 165. Ross PJ, Teoh EM, A’hern RP, Rhys-Evans PH, Harrington KJ, Nutting CM, Gore ME. Epirubicin, cisplatin and protracted venous infusion 5-Fluorouracil chemotherapy for advanced salivary adenoid cystic carcinoma. Clin Oncol (R Coll Radiol). 2009 May;21(4):311-4.
  166. 166. Pandha H, D’Ambrosio C, Heenan S, Hyde N, Di Palma S, Nutting C, Relph K, Harrington K. Indium-labelled autologous dendritic cells migrate to local lymph nodes after intratumoural injection in head and neck cancer patients. Clin Oncol (R Coll Radiol). 2009 May;21(4):363-4.
  167. 167. Newbold K, Castellano I, Charles-Edwards E, Mears D, Sohaib A, Leach M, Rhys-Evans P, Clarke P, Fisher C, Harrington K, Nutting C. An exploratory study into the role of dynamic contrast-enhanced magnetic resonance imaging or perfusion computed tomography for detection of intratumoral hypoxia in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):29-37.
  168. 168. Rogers SJ, Box C, Chambers P, Barbachano Y, Nutting CM, Rhŷs-Evans P, Workman P, Harrington KJ, Eccles SA. Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck. J Pathol. 2009 May;218(1):122-30.
  169. 169. Kazi R, Rhys-Evans P, Nutting CM, Harrington KJ. The great debate: stroboscopy vs high- speed imaging for assessment of alaryngeal phonation. J Cancer Res Ther. 2009 Apr-Jun;5(2):121-3.
  170. 170. Harrington KJ, El-Hariry IA, Holford CS, Lusinchi A, Nutting CM, Rosine D, Tanay M, Deutsch E, Matthews J, D’Ambrosio C, Turner SJ, Pandeshwara JS, Bourhis J. Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2009 Mar 1;27(7):1100-7.
  171. 171. Kazi R, Kanagalingam J, Venkitaraman R, Prasad V, Clarke P, Nutting CM, Rhys-Evans P, Harrington KJ. Electroglottographic and perceptual evaluation of tracheoesophageal speech. J Voice. 2009 Mar;23(2):247-54.
  172. 172. Bhide SA, Ahmed M, Rengarajan V, Powell C, Miah A, Newbold K, Nutting CM, Harrington KJ. Anemia during sequential induction chemotherapy and chemoradiation for head and neck cancer: the impact of blood transfusion on treatment outcome. Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):391-8.
  173. 173. Agrawal VK, Copeland KM, Barbachano Y, Rahim A, Seth R, White CL, Hingorani M, Nutting CM, Kelly M, Harris P, Pandha H, Melcher AA, Vile RG, Porter C, Harrington KJ. Microvascular free tissue transfer for gene delivery: in vivo evaluation of different routes of plasmid and adenoviral delivery. Gene Ther. 2009 Jan;16(1):78-92.
  174. 174. Wong WL, Nutting C, Dunn J, Fisher S, MacLennan K, MacCabe C, Mehanna H. Advanced head and neck cancer: is there a role for fluorodeoxyglucose PET/computed tomography? Nucl Med Commun. 2009 Jan;30(1):2-4.
  175. 175. Hingorani M, White CL, Merron A, Peerlinck I, Gore ME, Slade A, Scott SD, Nutting CM, Pandha HS, Melcher AA, Vile RG, Vassaux G, Harrington KJ. Inhibition of repair of radiation-induced DNA damage enhances gene expression from replication-defective adenoviral vectors. Cancer Res. 2008 Dec 1;68(23):9771-8.
  176. 176. Singh A, Kazi R, De Cordova J, Nutting CM, Clarke P, Harrington KJ, RhysEvans P. Multidimensional assessment of voice after vertical partial laryngectomy: a comparison with normal and total laryngectomy voice. J Voice. 2008 Nov;22(6):740-5.
  177. 177. Nutting CM, Robinson M, Birchall M. Survival from laryngeal cancer in England and Wales up to 2001. Br J Cancer. 2008 Sep 23;99 Suppl 1:S38-9.
  178. 178. Hingorani M, White CL, Zaidi S, Merron A, Peerlinck I, Gore ME, Nutting CM, Pandha HS, Melcher AA, Vile RG, Vassaux G, Harrington KJ. Radiation-mediated up-regulation of gene expression from replication-defective adenoviral vectors: implications for sodium iodide symporter gene therapy. Clin Cancer Res. 2008 Aug 1;14(15):4915-24.
  179. 179. Bhide SA, Ahmed M, Barbachano Y, Newbold K, Harrington KJ, Nutting CM. Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head-and-neck cancer. Br J Cancer. 2008 Jul 8;99(1):57-62.
  180. 180. Kazi R, Johnson C, Prasad V, De Cordova J, Venkitaraman R, Nutting CM, Clarke P, Evans PR, Harrington KJ. Quality of life outcome measures following partial glossectomy: assessment using the UW-QOL scale. J Cancer Res Ther. 2008 Jul-Sep;4(3):116-20.
  181. 181. Jankowska P, Teoh EM, Fisher C, Rhys Evans P, Nutting CM, Harrington KJ. Case report. Isolated intrathyroid metastasis from undifferentiated and squamous carcinoma of the head and neck: the case for surgery and re-irradiation. Br J Radiol. 2008 Jun;81(966):e154-61.
  182. 182. Kazi R, Venkitaraman R, Johnson C, Prasad V, Clarke P, Newbold K, Rhys-Evans P, Nutting C, Harrington K. Prospective, longitudinal electroglottographic study of voice recovery following accelerated hypofractionated radiotherapy for T1/T2 larynx cancer. Radiother Oncol. 2008 May;87(2):230-6.
  183. 183. Nutting CM, Bhide SA, Harrington KJ. Treatment of head and neck cancer. N Engl J Med. 2008 Mar 6;358(10):1076-7; author reply 1077-8.
  184. 184. Singh A, Kazi R, Venkitaraman R, Kapoor K, Nutting C, Clarke P, Rhys Evans P, Harrington K. Does flexible videostroboscopy compare with rigid videostroboscopy in the assessment of the neoglottis? A preliminary report. Clin Otolaryngol. 2008 Feb;33(1):60-3.
  185. 185. Kazi R, Venkitaraman R, Johnson C, Prasad V, Clarke P, Rhys-Evans P, Nutting CM, Harrington KJ. Electroglottographic comparison of voice outcomes in patients with advanced laryngopharyngeal cancer treated by chemoradiotherapy or total laryngectomy. Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):344-52.
  186. 186. Lee B, Cook G, John L, Harrington K, Nutting C. Follicular thyroid carcinoma metastasis to the esophagus detected by 18FDG PET/CT. Thyroid. 2008 Feb;18(2):267-71.
  187. 187. Newbold KL, Partridge M, Cook G, Sharma B, Rhys-Evans P, Harrington KJ, Nutting CM. Evaluation of the role of 18FDG-PET/CT in radiotherapy target definition in patients with head and neck cancer. Acta Oncol. 2008;47(7):1229-36.

Arrange a
Consultation

Complete our simple contact form to get in touch.

Read what others say